FindTrial
Sign In

Result Analysis of Total Hip Replacement in Sickle Cell Disease

An Outcome Analysis of Total Hip Arthroplasty in Sickle Cell Disease - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067673
Enrollment
50
Registered
2024-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M878- Other osteonecrosis Health Condition 2: M878- Other osteonecrosis

Interventions

Intervention1: NIL: NA Control Intervention1: NIL: NA

Sponsors

Datta Meghe Institute of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All Sickle Cell Disease patients eligible to undergo Total Hip Arthroplasty

Exclusion criteria

Exclusion criteria: 1. Patients undergoing Revision Total Hip Replacement 2. Patients with congenital anomalies of hip 3. Patients with a neurological deficit of the lower limb 4. Patients with ipsilateral knee/ankle/foot/Spine pathologies

Design outcomes

Primary

MeasureTime frame
The study through the perioperative clinical outcome analysis, Functional outcome analysis in terms of VAS Score, Modified Harris Hip Score and Radiological outcome analysis through pre-operative M.R.I. and X-ray in the pre-operative and postoperative period in Sickle cell disease patients following Total Hip Arthroplasty.Timepoint: Pre-operative period, post-operatively within 2 weeks and follow up visits at 6-8 weeks, 12-14 weeks—

Secondary

MeasureTime frame
To outline the perioperative complications, problems, and difficulties in sickle cell disease patients undergoing total hip arthroplasty. Further, it offers a comparative outcome analysis of sickle cell disease patients and non-sickle cell disease patients undergoing Total hip arthroplasty.Timepoint: Pre-operative period, post-operatively within 2 weeks and follow up visits at 6-8 weeks, 12-14 weeks—

Countries

India

Contacts

Public ContactDr Sandeep Shrivastava

Datta Meghe Institute of Higher Education and Research

drsandeepshrivastava@hotmail.com9765404068

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026